News
11h
Pharmaceutical Technology on MSNBig pharma braces for revenue headwinds as patent expiries loom"Big pharma braces for revenue headwinds as patent expiries loom" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Investigators studied apixaban pharmacokinetics, pharmacodynamics, and hemorrhage risk by kidney function. Kidney function is a major predictor of hemorrhage among patients with atrial fibrillation ...
A recent study published in JAMA has found that certain blood pressure medications may raise the risk of serious bleeding in ...
10d
MedPage Today on MSNOzempic Tied to Lower Dementia Risk; Ear Wax and Parkinson's; APOE4 and ICHPeople with type 2 diabetes who used semaglutide (Ozempic) versus other drugs had a lower risk of Alzheimer's disease and ...
About a month ago, I woke up without hearing in my left ear. I initially suspected a wax blockage or a blocked eustachian tube but eventually realized ...
CHICAGO — For patients with cancer requiring extended anticoagulant therapy, a strategy of reduced-dose apixaban was noninferior to full-dose apixaban for prevention of cancer-associated ...
Bristol-Myers Squibb provided the apixaban free of charge. It was an investigator- sponsored study coordinated by Assistance Publique des Hôpitaux de Paris (AP-HP).
For people with HIV and atrial fibrillation (Afib or AF), certain oral anticoagulants (OACs) may carry a higher bleeding risk than others, according to a study based on Medicare records. From a ...
News Release 31-Oct-2024 Apixaban vs aspirin in patients with cancer and cryptogenic stroke Peer-Reviewed Publication Ochsner Health System ...
Apixaban is a generic oral tablet that’s prescribed for certain types of blood clots. It’s available as the brand-name drug Eliquis. The cost of apixaban, with and without insurance, can ...
Apixaban is a generic prescription drug that’s used to treat or prevent certain blood clots. Apixaban’s cost may depend on factors such as your dosage, whether you have health insurance, and ...
Prophylaxis with apixaban (Eliquis) failed to reduce the rate of venous thromboembolism (VTE) in children with newly diagnosed acute lymphoblastic leukemia or lymphoma, according to results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results